Clinical trials: Metastatic Solid Tumor
Metastatic Cancer, Metastatic Colorectal Cancer
Study of OB-002 in Patients With Refractory Metastatic Cancer
This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two…
- Conditions
- Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- NCT05940844
- Testing
- OB-002
- Sponsor
- Orion Biotechnology Polska Sp. z o.o.
Advanced Solid Tumors
Study of E7389 in Patients With Advanced Solid Tumors
To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.
- Trial name
- NCT00069264
- Testing
- E7389
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumors
A Study of EMB-02 in Participants With Advanced Solid Tumors
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds.
- Trial name
- NCT04618393
- Testing
- EMB-02
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 47 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Endometrial Cancer, Gastric Cancer
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid…
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
- Trial name
- NCT05489211
- Testing
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil
- Where
- 96 sites in United States, Canada and 12 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Salivary Gland Tumor, Urothelial Carcinoma
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that…
- Conditions
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
- Trial name
- NCT04969835
- Testing
- AVA6000
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 158 people
- Sponsor
- Avacta Life Sciences Ltd
Advanced Solid Tumors
A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
The aim of this study is to determine the safety, tolerability and anti-tumoral activity of autologous T cells transduced with a T cell receptor specific for MAGE-A1 in eligible patients with advanced solid tumors.
- Trial name
- IMAG1NE (NCT05430555)
- Testing
- Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
- Where
- 14 sites in Belgium, Germany and 3 more
- Volunteers
- 23 people
- Sponsor
- T-knife GmbH
Advanced Solid Tumor, Metastatic Solid Tumor
Safety and Early Signs of Efficacy of IL12-L19L19.
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune…
- Trial name
- DODEKA (NCT04471987)
- Testing
- IL12-L19L19
- Where
- 11 sites in Germany, Italy and 1 more
- Volunteers
- 80 people
- Sponsor
- Philogen S.p.A.
Metastatic Breast Cancer
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours.
- Trial name
- NCT07580833
- Testing
- Oral Paclitaxel in combination with Encequidar tablet
- Volunteers
- 46 people
- Sponsor
- Health Hope Pharma
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Solid Tumors, Non-Hodgkin Lymphoma
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, multicenter study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma.
- Trial name
- NCT03707093
- Testing
- ADG106
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Adagene Inc
Solid Tumor (Phase I)
This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.
The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers.
- Trial name
- NCT07797907
- Testing
- BD200
- Volunteers
- 110 people
- Sponsor
- Biolojic Design Ltd.
Breast Neoplasms, Solid Tumors
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors.
- Conditions
- Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation
- Trial name
- PIKYMA-01 (NCT07861932)
- Testing
- K-1728, Fulvestrant, Palbociclib
- Volunteers
- 110 people
- Sponsor
- KymaThera, Inc.
Solid Tumor
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and…
- Trial name
- NCT07003321
- Testing
- HRS-4508 tablet
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Leptomeningeal Metastasis
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular…
- Trial name
- CA2024-LM-001 (NCT07098806)
- Testing
- 186RNL
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Cerenome
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or…
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Trial name
- NCT01379534
- Testing
- TKI258
- Where
- 45 sites in United States, Brazil and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
Solid Tumor, Lymphoma, Malignant
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
The purpose of this study is to assess the pharmacokinetics (PK) of enzastaurin and its metabolites in native Chinese participants with advanced and/or metastatic solid tumors or lymphoma.
- Trial name
- NCT01432951
- Testing
- Enzastaurin
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Colorectal Cancer
L19TNFα in Patients With Advanced Solid Tumors
The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues.
- Trial name
- NCT01253837
- Testing
- L19TNFa
- Where
- 2 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
The purpose of this study is to determine the following: 1. Find the maximum tolerated dose of E7050 when given in combination with cisplatin and capecitabine in patients with advance or metastatic solid tumors, and 2) Whether…
- Trial name
- NCT01355302
- Testing
- E7050, cisplatin, capecitabine
- Where
- 19 sites in United States, Russia and 2 more
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.